Skip to the main content

Original scientific paper

TERAPIJA BAZALNIM INZULINOM U BOLESNIKA SA ŠEĆERNOM BOLEŠĆU TIPA 2; USPOREDBA UČINKA I NUSPOJAVA INZULINSKOG ANALOGA GLARGINA I HUMANOG (NPH, NEUTRAL PROTAMINE HAGEDORN) INZULINA

PETRA KLANAC ; University of Zagreb School of Medicine, Zagreb, Croatia
MARKO KAŠTELAN ; University of Zagreb School of Medicine, Zagreb, Croatia
IVANA KRALJEVIĆ ; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
TOMISLAV BULUM ; University of Zagreb School of Medicine, Zagreb, Croatia; University of Zagreb School of Medicine, Department of Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, Zagreb, Croatia
ANELA NOVAK ; University of Split School of Medicine, Department of Endocrinology, University Hospital Center Split, Split, Croatia
ANNEMARIE BALAŠKO ; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MAJA JURIĆ SAMARDŽIĆ ; Department of Internal Medicine, General Hospital Slavonski Brod, Slavonski Brod, Croatia
KARIN ZIBAR TOMŠIĆ ; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MAJA BARETIĆ ; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MAJA MIKOLAJ KIRIĆ ; Department of Internal Medicine, County Hospital Čakovec, Čakovec, Croatia
TANJA MILIČEVIĆ MILARDOVIĆ ; University of Split School of Medicine, Department of Endocrinology, University Hospital Center Split, Split, Croatia
HRVOJE POPOVAC ; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
TANJA ŠKORIĆ POLOVINA ; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
MARIJA TRIPOLSKI ; Department of Endocrinology, Clinic for Internal Medicine, University Hospital Center Osijek, Osijek, Croatia
TATJANA BAČUN ; Department of Endocrinology, Clinic for Internal Medicine, University Hospital Center Osijek, Osijek, Croatia; Faculty of Medicine, University Josip Juraj Strossmayer in Osijek, Osijek, Croatia
MIRSALA SOLAK ; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
SIDBELA ZUKANOVIĆ ; Department of Internal Medicine, General Hospital Slavonski Brod, Slavonski Brod, Croatia
TINA DUŠEK ; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia
DARKO KAŠTELAN ; University of Zagreb School of Medicine, Zagreb, Croatia; Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia *

* Corresponding author.


Full text: english pdf 161 Kb

page 133-139

downloads: 152

cite


Abstract

Uvod: Terapija inzulinom često je potrebna za postizanje odgovarajućeg nadzora glikemije u bolesnika sa šećernom bolešću tipa 2 (ŠBT2). U tu se svrhu trenutačno u kliničkoj praksi najčešće koristi inzulinski analog glargin, a znatno rjeđe jeftiniji humani inzulin NPH (Neutral Protamine Hagedorn). Metode: U ovom opservacijskom multicentričnom istraživanju usporedili smo učinkovitost i sigurnost inzulina glargina i humanog NPH inzulina. Tijekom šestomjesečnog razdoblja praćenja promatrane su dvije skupine bolesnika sa ŠBT2. U jednoj skupini primijenjen je inzulin NPH (n = 53), dok je drugoj skupini primijenjen inzulin glargin (n = 48). Rezultati: Nakon šest mjeseci obje skupine bolesnika postigle su istu razinu hemoglobina A1c (HbA1c) (7,5 ± 1 %). U obje skupine uočeno je blago statistički neznačajno povećanje tjelesne mase. Dnevna doza inzulina (iskazana u međunarodnim jedinicama, IU, od engl. international units) bila je značajno veća u skupini koja je primala glargin nego u skupini koja je primala inzulin NPH (22,4 ± 8,5 IU prema 18,6 ± 7,8 IU). Učestalost epizoda hipoglikemije bila je podjednaka u objema skupinama. Zaključak: Naše istraživanje nije pokazalo značajnu razliku ni u riziku od hipoglikemije niti u učinkovitosti između inzulina glargina i inzulina NPH u bolesnika s ŠBT2. Sukladno tome, naši rezultati upućuju na to da humani inzulin NPH može biti učinkovit i siguran izbor liječenja za većinu bolesnika sa ŠBT2.

Keywords

šećerna bolest tip 2; inzulin glargin; inzulin NPH; hipoglikemija; dugodjelujući inzulin

Hrčak ID:

331219

URI

https://hrcak.srce.hr/331219

Publication date:

16.5.2025.

Article data in other languages: english

Visits: 371 *